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Despite significant advances in preventive, medical, and interventional management, coronary artery
disease remains the leading cause of death worldwide. We now know that in the majority of acute
coronary syndromes, a thrombotic event is triggered either by the rupture or erosion of the so-called
high-risk or ‘vulnerable’ plaque. However, accurately identifying the individual who is at significant
risk of acute event remains the holy grail of preventive cardiology. To better stratify an individual's risk of
developing and suffering a cardiovascular event, biomarkers are needed that can accurately predict
coronary events and, if possible, monitor disease activity in response to medical or interventional
therapies. In order to be able to understand the association of these biomarkers with the morphological
substrate of high-risk plaques, intravascular imaging modalities can provide invaluable assistance. Novel
imaging tools such as optical coherence tomography (OCT) have not only helped in identifying athero-
sclerotic plaque characteristics that are unstable but also in estimating global plaque burden. In this
study, we provide an overview of our current knowledge of association of various inflammatory markers
with atherosclerotic plaque characteristics seen on OCT.
© 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ischemic heart disease remains the leading cause of death
worldwide, despite advances in medical and interventional thera-
pies.1 It is now widely accepted that atherosclerosis is an inflam-
matory process.2 All the key steps from initiation and progression
of atherosclerosis to eventual plaque rupture or erosion and
thrombus formation involve inflammatory pathways.3 Studies from
cellular and molecular biology have shown how inflammatory
pathways differ in each step of atherosclerosis.2 It is now well
established that molecules such as cytokines and adhesion mole-
cules alter endothelial integrity, through which cells such asl, Hyderabad, 500019, India.
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al coherence tomography, Hemonocytes gain entry and alter the structural integrity of the
arterial wall. Ensuing lipid accumulation and plaque progression
involves degradation of interstitial collagen by matrix metal-
loproteinase.4 Both local and systemic inflammation contribute to
plaque rupture with a subsequent role of activated platelets in
thrombus formation and propagation by binding with monocytes.
Yet again, it is the dynamic interplay between cells such as platelets
and monocytes with molecules such as tissue factor and P-selectin
glycoprotein ligand 1 that mediates thrombus formation and
propagation. A greater knowledge of the role played by various
inflammatory cells and molecules involved in atherogenesis may
translate into the development of biomarkers5,6 that can be used to
screen individuals who are at risk and to monitor interventions
aimed at ameliorating atherosclerosis. (see Table 1)
The majority of knowledge regarding the pathophysiology of
atherosclerosis is based on histology. A vulnerable plaque is defined
as a coronary atherosclerotic plaque that is prone to rupture ands is an open access article under the CC BY-NC-ND license (http://creativecommons.
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Table 1
Association of inflammatory biomarkers and plaque morphology in patients with ACS.
Study Population Inflammatory marker Association with plaque morphology
Inflammatory biomarkers
Raffel et al. 17 32 ACS and 11 SA patients WBC count  WBC count correlated with cap thickness
and macrophage density of the plaque
 CRP levels higher in TCFA versus non-
TCFA lesions
Kashiwagi et al. 20 47 ACS patients CRP  CRP levels higher in TCFA versus non-
TCFA lesions
Fujii et al. 21 35 AMI and 20 SA patients CRP  CRP independent predictor of multiple
TCFA in the coronary tree in AMI
Bouki et al. 18 32 ACS and 14 SA patients CRP, IL-18  CRP and IL-18 levels higher in TCFA
versus non-TCFA lesions
 CRP and IL-18 levels higher in ruptured
plaques versus non-ruptured plaques
 IL-18 levels lower in plaques with
calcification
 CRP levels independent predictor of
ruptured plaque
Li et al. 12 AMI, 23 UA and 11 SA patients WBC count, CRP, IL-18, TNFa  Cap thickness inversely correlated with
WBC count and CRP, IL-18, and TNFa
levels
 WBC count and CRP, IL-18, and TNFa
levels higher in TCFA versus non-TCFA
lesions
 No association for any factor with plaque
rupture
 CRP levels independent predictor of TCFA
Nicolli et al. 19 50 non-ST elevation ACS patients CRP, MPO, MMP-9, MMP-2,
Cystatin-C
 CRP and MMP-9 levels higher in plaque
rupture compared to erosion and severe
stenosis without thrombus
 MPO levels higher in plaque erosion
compared to rupture and severe
stenosis without thrombus
 Cystatin-C levels higher in severe stenosis
without thrombus compared to plaque
rupture or erosion
 No association of MMP-2 with plaque
morphology
Ferrante et al. 47 25 AMI patients CRP, MPO  No difference in CRP levels for plaque
rupture versus plaque erosion
 Elevated MPO levels in plaque erosion
versus plaque rupture
Koga et al. 22 28 ACS and 47 SA patients CRP, pentraxin-3  Levels of pentraxin-3, but not CRP, were
higher in TCFA versus non-TCFA lesions,
both in ACS and SA lesions
Ozaki et al. 34 25 AMI and 20 UA patients PSGL-1 expression in circulating
monocytes
 Increased PSGL-1 expression in circu-
lating monocytes in lesions with plaque
rupture
Matsuo et al.36 53 ACS and 49 SA patients MDA-LDL, CRP  Higher CRP levels but no difference in
MDA-LDL levels in TCFA versus non-
TCFA lesions in ACS
 Significantly higher MDA-LDL levels in
ruptured TCFA versus non-ruptured TCFA
in ACS
Teraguchi et al. 31 37 AMI patients MAGE, circulating monocytes  Increased MAGE in plaque rupture
compared to non-ruptured plaque
 Increased circulating monocytes in
plaque rupture
Sun et al. 25 81 CAD patients Neopterin  Higher levels of Neopterin in non-culprit
plaque that have TCFA, smaller FCT, and
more macrophages
Wakabayashi et al. 41 59 ACS patients Eicosapentaenoic acid/Arachidonic
acid
 Low EPA/AA ratio in ACS patients with
TCFA
Lee et al. 43 206 SA patients Troponin  Elevated cTnI group has frequent TCFAs, a
greater lipid arc, and longer lipid length
Gu et al. 46 24 ACS patients Lp-PLA2  Positive correlation between Lp-PLA2
activity, FCT, and plaque volume
Abbreviations: ACS ¼ Acute coronary syndrome, SA¼ Stable angina, AMI ¼ Acute myocardial infarction, CAD ¼ Coronary artery disease, UA ¼ unstable angina, WBC ¼ white
blood cells, TCFA ¼ Thin cap fibroatheroma, CRP¼C-reactive protein, IL ¼ interleukin, TNFa ¼ tumor necrosis factor alpha, MPO ¼ myeloperoxidase, MMP ¼ Matrix metal-
loproteinase, PSGL-1¼ P-selectin glycoprotein ligand-1, MDA-LDL¼malondialdehyde-modified low-density lipoprotein, MAGE¼mean amplitude of glycemic excursion, FCT
e Fibrous cap thickness, Lp-PLA2 ¼ Lipoprotein-associated phospholipase A2.
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fibroatheroma (TCFA), a plaque with thin fibrous cap (<65 mm),
macrophage infiltration, and large necrotic core, is currently
considered the main phenotype of vulnerable plaque.8 Autopsy
studies from patients who have suffered sudden cardiac death
revealed the substrate for atherothrombosis to be plaque rupture in
60-70% of the cases, plaque erosion in 20-30% of the cases, and
calcified nodules in the rest.9 Autopsy studies have, however,
several limitations in that they represent the far-end of the clinical
spectrum and ex vivo specimens need heavy processing and fixa-
tionwith formalinwhich lead to some degradation.10 Intracoronary
imaging modalities such as optical coherence tomography (OCT)
can be used for the in vivo imaging of coronary arteries and
studying the atherosclerotic plaque characteristics due to high-
resolution images (15 mm) obtained by near-infrared light.11-13 In
their seminal study, Jang et al visualized the atherosclerotic plaque
characteristics of culprit lesions by OCT in a cohort of 57 patients
presenting with ST segment elevation myocardial infarction
(STEMI, n¼ 20), non STEMI (NSTEMI, n¼ 20), and stable angina (SA,
n ¼ 17).14 OCT-identified TCFA and disrupted plaques were more
prevalent in acute coronary syndromes (ACS), in contrast to plaques
from stable coronary artery disease patients that had a higher
incidence of calcifications. These findings were concordant with an
ex vivo study conducted by the same group15 and previously re-
ported autopsy studies.16
As new data showing associations between biomarkers and
cardiovascular events emerge, the finding of an association be-
tween the circulating levels of biomarkers and plaque morphology
by OCT can provide new insights into the role of these biomarkers
and the implicated mechanisms, thus providing more effective risk
stratification.
The aim of this manuscript is to review the literature on the
relationship between inflammatory markers and plaque vulnera-
bility using OCT.
2. Association with White blood cells (WBC)
Raffel et al conducted one of the first studies that correlated
inflammatory markers with plaque characteristics using OCT.17 The
relationship between the peripheral WBC count, local macrophage
density over the fibrous cap, other morphological features, and
presence of TCFA was evaluated in 43 patients undergoing angi-
ography for ACS or SA. Patients with lipid-rich plaques had higher
WBC counts in comparison to those with nonelipid-rich plaques,
and there was a significant linear relationship between WBC count
and plaque fibrous cap macrophage density irrespective of the
presenting syndrome. Moreover, there was a strong linear rela-
tionship between WBC count and macrophage density in culprit
plaque when compared to remote plaque. Further, an inverse linear
relationship between WBC count and plaque macrophage density
with fibrous cap thickness was found. Patients having culprit pla-
que with TCFA morphology had a higher median WBC count
compared with those with culprit plaque without TCFA. Although
this study revealed a strong association between WBC and the
presence of vulnerable plaque, it did not provide answers with
respect to a mechanistic role of WBC in plaque destabilization.
3. Association with C- reactive protein (CRP), high sensitivity
(hs) CRP, & Interleukins
Bouki et al evaluated OCT-derived plaque characteristics be-
tween ACS and SA and correlated with hs-CRP and Interleukin
(IL18) in 46 patients (32 ACS and 14 SA).18 They noted more
ruptured plaques and TCFA and lipid-rich plaques in patients pre-
senting with ACS and more calcific plaques in patients presentingPlease cite this article as: Koganti S et al., Association of systemic inflam
atherosclerotic plaque by intravascular optical coherence tomography, Hewith SA. IL18 and hs-CRP were significantly elevated in patients
presenting with ACS when compared to those with SA and corre-
lated with presence of TCFA. Furthermore, on multivariate analysis,
hs-CRP was found to independently predict the presence of plaque
rupture and detect it with a high degree of sensitivity and speci-
ficity. Niccoli et al sought to evaluate the relationship between hs-
CRP, Matrix metalloproteinase (MMP)-9, MMP-2, Myeloperoxidase
(MPO), and CystatineC with the presence of plaque rupture, plaque
erosion, and significant stenosis with no thrombus.19 Their cohort
of 84 patients consisted of 50 NSTE-ACS and 34 SA patients. Addi-
tionally, there was no difference in plaque characteristics between
ACS and SA in culprit artery only OCT. However, hs-CRP and MMP9
were associated with the presence of plaque rupture, MPO was
associated with the presence of plaque erosion, and cystatinec was
associated with the presence of significant stenosis without any
superimposed thrombosis. Kashiwagi et al evaluated the relation-
ship between coronary arterial remodeling, fibrous cap thickness
(FCT), and hs-CRP levels in 47 consecutive patients presenting with
ACS. In this culprit plaque only study, arterial remodeling was
assessed by intravascular ultrasound (IVUS), and FCT wasmeasured
by OCT.20 In total, positive remodeling (PR) was observed in 17 out
of 47 patients, and negative or intermittent remodeling was
observed in the remainder. Lipid-rich plaques and TCFA were more
frequent in the PR group. Furthermore, high levels of hs-CRP were
observed in the group with PR, as well as in thosewith documented
TCFA. In a 3-vessel OCT study involving 35 AMI and 20 SA patients,
Fujii et al showed hs-CRP levels to be associated with the presence
of multiple TCFAs in ACS patients.21
4. Association with other novel inflammatory markers
4.1. Pentraxin 3
Pentraxin 3 (PTX3) is an acute phase reactant and member of
the pentraxin superfamily along with CRP. High levels of PTX3 are
locally expressed in vascular endothelial and smoothmuscle cells in
human atherosclerotic lesions. Previously, PTX-3 has been shown
to be an early indicator of acute myocardial infarction.22 Koga
et al evaluated the association of PTX-3 with the presence of TCFA
and arterial remodeling index in 75 patients with CAD, of which 28
were diagnosed to have ACS and the remaining had SA. Intravas-
cular imaging was carried out with OCT and IVUS. The levels of
PTX3were significantly higher in patients with TCFA and correlated
inversely with FCT and positively with the remodeling index.
Multivariate logistic regression analysis showed that a higher PTX3
level was the most powerful predictor of TCFA with receiver oper-
ating curve analysis showing that PTX-3 levels >3.24 ng/ml could
predict the presence of TCFA with 84% sensitivity and 86%
specificity.
4.2. Neopterin
Neopterin, a pteridine derivative, is an intermediate metabolite
in guanosine triphosphate metabolism and in tetrahydrobiopterin
biosynthesis. Neopterin which is secreted by activated macro-
phages has previously been shown to be elevated in patients with
ACS than SA.23 Furthermore, Kaski et al showed that elevated
neopterin levels at baseline in a cohort of patients with NSTE-ACS
were independently associated with cardiac death, acute myocar-
dial infarction, and unstable angina after six months.24 More
recently, Sun et al evaluated the levels of neopterin from peripheral
venous blood in patients presenting with NSTE-ACS and SA, and
evaluated a possible association with vulnerable plaque features
from noneculprit plaques.25 Higher levels of neopterin were
detected in non-culprit plaques with vulnerable features such asmatory biomarkers with morphological characteristics of coronary
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However, a possible association of neopterin levels with culprit
lesion morphology remains elusive, as it was not evaluated in the
context of this study.
4.3. Myeloperoxidase
MPO, a hemoprotein released upon neutrophil activation, has
been shown to predict the outcome of patients with ACS26,27 and is
considered to be a marker of plaque vulnerability.27 A study eval-
uating the association of MPO with plaque erosion or rupture in
patients presenting with ACS has shown significantly higher MPO
blood levels in eroded plaques. Furthermore, overlying thrombus in
eroded plaques had significantly higher MPO levels when
compared to thrombus from ruptured plaques in postmortem
coronary samples of sudden death cases. Moreover, MPO levels
were not elevated in the fibrous cap near the rupture or the
interface between thrombus and artery in eroded plaques but were
significantly elevated in the thrombus overlying eroded plaques,
suggesting a role in thrombus formation. This could be explained by
a mechanism including hyaluronan-mediated loss of endothelial
layer followed by platelet adhesion and subsequent thrombus for-
mation.28 Further, in line with previous studies, MPO levels were
elevated in smokers when compared to non-smokers,29 although
this could be a confounder given the high percentage of smokers in
the group with plaque erosion. In the same study, investigators
showed no such discriminatory role for CRP.
5. Impact of glucose fluctuation, monocyte subsets, &
P-selectin glycoprotein ligand 1 (PSGL-1)
Elevated blood glucose levels are commonly seen in patients
presenting with AMI secondary to excessive sympathetic drive30*.
This pattern is seen in both diabetics and non-diabetics. However, it
is not known if there is any correlation between glucose levels at
the time of presentation with AMI or during recovery with
atherosclerotic plaque characteristics. In a small study involving 37
consecutive patients with AMI that underwent OCT, Teraguchi
et al showed that glycemic variability, expressed as the mean
amplitude of glycemic excursion (MAGE), was significantly higher
in patients with plaque rupture than non-rupture patients.31 It is
important to note that variability in glucose measurements was
carried out prospectively up to 7 days, not allowing the evaluation
of a possible prospective association of fluctuation in glucose levels
with a future AMI. Furthermore, MAGE correlated positively and
significantly with levels of CD14-bright CD16fl-monocytes, which
in turn were higher in patients with plaque rupture than in non-
rupture patients. Whilst this suggests that glucose fluctuation is
pro-inflammatory, no other correlation with traditional inflam-
matory markers such as WCC, CRP, or cytokines was shown. Thus,
this study at best hypothesizes that dynamic glucose fluctuation in
diabetic and non-diabetic patients is potentially associated with
plaque rupture.
The role of monocytes in atherosclerosis is well established.32
Monocytes play a crucial role in the formation and propagation of
thrombus in ACS patients. Activated platelets in ACS express
Peselectin, which is an adhesion molecule to which monocytes
bind through PSGL-1 resulting in platelet-rich arterial thrombi.33 In
another monocyte-based study, the expression of PSGL-1 in circu-
lating peripheral CD14þþCD16þ monocytes was significantly
elevated in AMI patients with plaque rupture and intracoronary
thrombus by OCT. Interestingly, similar levels of PSGL-1 were not
seen in plaque rupture associated with SA. Considering that
thrombus formation secondary to plaque rupture or erosion is
pathognomonic of ACS and that the culprit lesion in SA is usuallyPlease cite this article as: Koganti S et al., Association of systemic inflam
atherosclerotic plaque by intravascular optical coherence tomography, Heobstructive in nature, plaque rupture in SA seen on OCT is usually
an incidental finding that may have happened in the past with no
clinical sequelae. Therefore, at the time of identification, plaque
rupture is probably no longer acute, and as a result there is no
thrombus, thus explaining the normal PSGL-1 levels.34
6. Oxidized low density lipoproteins (Ox-LDL)
Malondialdehyde-modified LDL (MDA-LDL) is an oxLDL that was
shown to be elevated in patients with ACS.35 Matsuo et al evaluated
the relationship between coronary plaque vulnerability assessed by
OCT and circulating MDA-LDL in stable and unstable CAD. The
circulating levels of MDA-LDL were significantly higher in patients
with ACS, in SAP patients with TCFA and in ACS patients with
ruptured TCFA.36 Similarly, experimental studies in mice have
shown a transient increase in plasma Ox-LDL during the progres-
sion of atherosclerosis; however, they do not allow to discriminate
whether the observed elevated MDA-LDL levels in patients with
vulnerable plaque are due to association or causation.37
7. N3 and n6 polyunsaturated fatty acids (PUFA)
Eicosapentaenoic acid (EPA), a member of n3 PUFA family, is
derived from fish oil and has a role in preventing cardiovascular
events.38 Arachidonic acid (AA), a member of n6 PUFA, is known to
promote CAD. Chronic imbalance of EPA & AA is known to promote
CAD.39 A low EPA/AA ratio has been shown to be associated with
thin cap fibroatheroma and wide lipid arc as seen on OCT in pa-
tients with stable angina.40 Similarly, in ACS patients, EPA/AA ratio
was noted to be significantly lower in patients with TCFA than in
those without TCFA.41 Addressing this imbalance through means
such as higher consumption of oily fish or fish oil supplements may
impart stability to atherosclerotic plaque but this has to be
confirmed by larger studies.
7.1. Troponin I
High sensitivity troponins at low levels were noted not only to
be present in a great majority of patients with stable CAD but were
also associated with the incidence of cardiovascular death and
heart failure.42 Lee et al compared clinical and atherosclerotic
plaque characteristics in patients undergoing PCI for stable CAD by
dividing them into two groups: one with cTnI 0.03 ng/ml and one
with cTnI <0.03 ng/ml.43 The group inwhich cTnI was elevated was
noted to have frequent TCFAs, a greater lipid arc, and longer lipid
length. Furthermore, periprocedural myocardial injury occurred
more frequently in the group with elevated cTnI, with OCT-
identified TCFA being an independent predictor. This study sug-
gests the presence of low levels of high sensitivity troponins in
some patients with CAD, which are associated with vulnerable
plaque and an adverse outcome. However, large-scale studies have
to be carried out to assess the feasibility of incorporating high
sensitivity troponin levels into traditional risk scoring systems to
see if it has a good discriminator value.
7.2. Lipoprotein-associated phospholipase A2 (Lp-PLA2)
Lp-PLA2 is an enzyme known to hydrolyze ox-LDL particles
leading to the production of byproducts that have been shown
through in vitro experiments to cause plaque instability.44 Prior
studies have shown association between higher levels of Lp-PLA2
mass and coronary events.45 Gu et al studied FCT and plaque vol-
ume in non-culprit lipid-rich plaques at baseline and after
12 months by using OCT and IVUS in 24 patients presenting with
ACS. A significant positive correlation was noted between Lp-PLA2matory biomarkers with morphological characteristics of coronary
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PLA2 measurement as a biomarker for progression of CAD, the
lack of any therapeutic benefit of direct inhibition of Lp-PLA2 ac-
tivity in the SOLID-TIMI52 study suggests that this is not a suitable
target for intervention.468. Summary
In summary, several studies, though limited by their relatively
small numbers of participants, have shown a good correlation be-
tween inflammatory markers and OCT-derived atherosclerotic
plaque characteristics. However, the causation or association is still
unclear, as predicting the levels of inflammatory markers and their
association with vulnerable plaque in the run-up to an acute event
is difficult. Furthermore, with the exception of traditional markers
such as CRP, hs-CRP, WBC, and Troponin, measuring novel inflam-
matorymarkers is cumbersome and is still at an experimental level.
These observations highlight the fact that research in this field is
still in its infancy and any conclusions are preliminary.9. Conclusion
Prospective long-term and larger studies with a simplified
means of assaying biomarkers are required before they can be
adopted into risk stratification models. Until then, the debate on
and pursuit of how best to predict the next acute coronary event
goes on.Conflict of interest
There is No conflict of interest.References
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